The estimated Net Worth of Miles Harrison is at least 412 千$ dollars as of 25 May 2024. Mr. Harrison owns over 8,636 units of Castle Biosciences stock worth over 412,420$ and over the last 5 years he sold CSTL stock worth over 0$. In addition, he makes 0$ as Independent Director at Castle Biosciences.
Miles has made over 3 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 8,636 units of CSTL stock worth 267,975$ on 25 May 2024.
The largest trade he's ever made was exercising 8,636 units of Castle Biosciences stock on 25 May 2024 worth over 267,975$. On average, Miles trades about 1,477 units every 79 days since 2020. As of 25 May 2024 he still owns at least 13,291 units of Castle Biosciences stock.
You can see the complete history of Mr. Harrison stock trades at the bottom of the page.
Miles D. Harrison serves as Independent Director of the Company. Since February 2016, Mr. Harrison has served as the North American president and general manager of Galderma Laboratories, L.P., the largest independent global dermatology company. Mr. Harrison also served as Galderma’s vice president and general manager of the Consumer Business Unit from August 2014 until February 2016. Prior to Galderma, Mr. Harrison spent most of his career at Novartis, a healthcare company. From June 1987 until February 2014, Mr. Harrison held multiple leadership positions of increasing responsibility across the consumer, oncology and pharmaceuticals businesses, most recently as vice president and head of global advocacy. Mr. Harrison holds a B.A. degree (Honors) in Geography from Sheffield Hallam University in the United Kingdom.
Miles Harrison is 55, he's been the Independent Director of Castle Biosciences since 2020. There are 8 older and 5 younger executives at Castle Biosciences. The oldest executive at Castle Biosciences, Inc. is David Kabakoff, 72, who is the Independent Director.
Miles's mailing address filed with the SEC is C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD, TX, 77546.
Over the last 5 years, insiders at Castle Biosciences have traded over 378,509,770$ worth of Castle Biosciences stock and bought 782,652 units worth 12,524,690$ . The most active insiders traders include Daniel Bradbury、Derek J Maetzold、Joseph C. Iii Cook. On average, Castle Biosciences executives and independent directors trade stock every 6 days with the average trade being worth of 632,640$. The most recent stock trade was executed by Derek J Maetzold on 9 September 2024, trading 2,586 units of CSTL stock currently worth 76,184$.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences executives and other stock owners filed with the SEC include: